Macular degeneration linked to aging immune cells

April 5, 2018, Washington University School of Medicine
Studying mice and cells from patients, vision researchers at Washington University School of Medicine in St. Louis found that as immune cells called macrophages get older, they are more likely to contribute to inflammation and abnormal blood vessel growth in the back of the eye. This can damage vision in patients with age-related macular degeneration. Credit: Danyel Cavazos/ Michael Worful

As people age, their immune systems age, too. And new research at Washington University School of Medicine in St. Louis suggests that aging immune cells increase the risk for age-related macular degeneration, a major cause of blindness in the United States.

Studying mice and from patients, the researchers found that as called macrophages age, they are more likely to contribute to the inflammation and growth that damage in macular degeneration.

Their findings are published April 5 in the journal JCI Insight.

"Drug treatments for macular degeneration aren't effective for some patients, who either have a minimal response or not response at all, and many patients continue to experience vision loss over the long term, even if they have a good initial response to treatment," said senior investigator Rajendra S. Apte, MD, PhD, the Paul A. Cibis Distinguished Professor of Ophthalmology and Visual Sciences. "But by understanding what happens with the immune cells in the eye, it may be possible to develop therapies to help patients who can't be helped with existing drugs."

In experiments in mice, Apte's team found that older macrophages carry larger amounts of short snippets of genetic material, called microRNAs, that govern how cells express genes. The researchers found significantly higher levels of microRNA-150 in macrophages in the eyes of older mice.

MicroRNAs help regulate many things in cells by binding to several genes to influence how those genes make proteins. In this study, the researchers found that microRNA-150 seemed to be guiding older macrophages toward promoting inflammation and abnormal blood vessel formation in a mouse model of macular degeneration.

Our immune systems can change as we get older, and now researchers at Washington University School of Medicine in St. Louis have found that as immune cells called macrophages age, the changes in those older cells can increase the risks for age-related macular degeneration, a major cause of blindness in the united states. Jim Dryden has more... Credit: Washington University BioMed Radio

The researchers also tested blood samples from human subjects with and without macular degeneration. The samples from those with macular degeneration also had significantly higher levels of microRNA-150 in their macrophages.

"We think microRNA-150 may be a potential therapeutic target, or at least a biomarker, for aggressive disease and risk of vision loss," said first author Jonathan B. Lin, an MD/PhD student at the School of Medicine.

In the United States, almost 11 million people have some form of age-related , with the number expected to top 22 million by 2050. It affects women more than men, and the majority of patients are Caucasian. One early symptom is blurry vision in which straight lines appear distorted. That can progress to darkness, whiteouts or blurry areas in the center of the visual field. The disease does not, by itself, lead to total blindness because peripheral vision remains unaffected. Although some therapies delay loss of central vision, no current treatments restore it completely.

"Macular degeneration therapies seem to be treating disease symptoms, rather than its cause," Lin said. "We focused on the role of macrophages in regulating inflammation and the growth of abnormal blood vessels to see whether it may be possible one day to help people who don't get much benefit from existing treatments and design therapies that may prevent progression to advanced forms of the disease."

Lin and Apte said if they could somehow reduce microRNA levels in macrophages, or alter one or more molecular pathways regulated by this microRNA, they might be able to lower levels of inflammation and interfere with abnormal in the eye. They also believe similar strategies eventually may help patients with other diseases related to aging.

"It's possible to envision immune-based therapies that would tweak the level of microRNAs so that these macrophage cells no longer contribute to disease," said Apte. "Such therapies are a long way off, and we need to do a lot more research, but if we could make these older cells more like the younger ones, we might be able to prevent a great deal of ."

Explore further: New clues found to vision loss in macular degeneration?

More information: Lin JB, Moolani HV, Sene A, Sidhu R, Kell P, Lin JB, Dong Z, Ban N, Ory DS, Apte RS. Macrophage microRNA-150 promotes pathological angiogenesis as seen in age-related macular degeneration. JCI Insight, vol. 3 (7), April 5, 2018. doi.org/10.1172/jci.insight.120157

Related Stories

New clues found to vision loss in macular degeneration?

August 11, 2015
Scientists have identified a pathway that leads to the formation of atypical blood vessels that can cause blindness in people with age-related macular degeneration.

Cholesterol-lowering eye drops could treat macular degeneration

April 2, 2013
A new study raises the intriguing possibility that drugs prescribed to lower cholesterol may be effective against macular degeneration, a blinding eye disease.

New model for hard-to-study form of blindness paves way for future research

September 6, 2017
Macular degeneration is the leading cause of vision loss in older adults, but scientists have long struggled to study and replicate key elements of the disease in the lab. A study published in the Proceedings of the National ...

Study shows daily aspirin intake can lead to blindness

October 5, 2011
(Medical Xpress) -- A new study published in Ophthalmology reveals that while taking a daily aspirin may reduce the risks of heart disease and stroke, a disturbing side effect has also been noted to increase the risk of developing ...

Experimental drug shows promise for sight-stealing eye condition

January 19, 2017
An experimental drug may one day make treatment simpler for patients suffering from vision-threatening age-related macular degeneration, researchers say.

Clinical trial tests cord-blood cells to treat macular degeneration

July 20, 2016
UIC is part of a national phase 2 clinical trial to evaluate the safety and tolerability of using cells derived from multipotent umbilical cord cells to treat age-related macular degeneration, the most common cause of vision ...

Recommended for you

Research debunks 'myth' that strenuous exercise suppresses the immune system

April 20, 2018
New research overturns a myth that has persisted for nearly four decades - that competing in endurance sports, like this weekend's London Marathon, suppresses the body's immune system and makes competitors more susceptible ...

Immune diversity among the KhoeSan population

April 20, 2018
A new study of the KhoeSan of Southern Africa has improved the understanding of immune diversity among the oldest surviving indigenous population in the world.

Psoriasis treated with compound derived from immune cells

April 18, 2018
A compound derived from immune cells treats psoriasis in mice and holds promise for other autoimmune diseases, according to a new study from Washington University School of Medicine in St. Louis.

Researchers uncover origin of virus-fighting plasma B cells

April 18, 2018
Plasma B cells, which move through the body releasing antibodies, are an important component of the body's fight against viral infections and other invaders. They are relatively rare, however, and increasing their ranks is ...

Your immune system holds the line against repeat invaders, thanks to this molecule

April 17, 2018
Memory T cells are a critical element of our immune system's historical archive. To prevent repeat infections, these cells retain a record of germs they've fought before.

New disease model to facilitate development of ALS and MS therapies

April 17, 2018
Researchers at Karolinska Institutet in Sweden have developed a new disease model for neurodegenerative diseases such as ALS and MS that can be used to develop new immunotherapies. The model is described in a publication ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.